GeoVax Labs (GOVX) to Release Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is projected to post its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect GeoVax Labs to post earnings of ($7.00) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

GeoVax Labs Stock Up 2.7%

GeoVax Labs stock opened at $1.54 on Wednesday. GeoVax Labs has a 52-week low of $1.26 and a 52-week high of $35.25. The firm has a market capitalization of $2.80 million, a price-to-earnings ratio of -0.04 and a beta of 3.81. The firm has a 50-day moving average price of $2.15 and a two-hundred day moving average price of $8.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the first quarter valued at approximately $27,000. HRT Financial LP acquired a new stake in GeoVax Labs in the fourth quarter worth approximately $31,000. Armistice Capital LLC bought a new position in GeoVax Labs during the 3rd quarter valued at $253,000. Finally, Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs during the 4th quarter valued at $104,000. 6.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GOVX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, February 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GeoVax Labs currently has a consensus rating of “Hold” and an average target price of $187.50.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.